Keyphrases
Human Endothelial Cells
100%
Ponatinib
100%
Tyrosine Kinase Inhibitor
66%
Vascular Adverse Events
66%
Human Umbilical Vein Endothelial Cells (HUVECs)
50%
Tube Formation
33%
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2)
33%
Control Cell
16%
Negative Effects
16%
Adverse Effects
16%
Cell Viability
16%
Cell Function
16%
Chronic Myeloid Leukemia
16%
Induced Apoptosis
16%
Imatinib
16%
Endothelial Progenitor Cells
16%
Antiangiogenic Activity
16%
Endothelial Cell Function
16%
Angiogenesis Model
16%
Nilotinib
16%
In Vitro Angiogenesis
16%
Medicine and Dentistry
Endothelial Cell
100%
Ponatinib
100%
Tyrosine-Kinase Inhibitor
66%
Adverse Event
66%
Human Umbilical Vein Endothelial Cell
50%
Vasculotropin Receptor 2
33%
Cell Function
33%
In Vitro
16%
Chronic Myelogenous Leukemia
16%
Programmed Cell Death
16%
Imatinib
16%
Endothelial Progenitor Cell
16%
Cell Viability
16%
Antiangiogenic Activity
16%
Nilotinib
16%
Angiogenesis Model
16%
Adverse Effect
16%
Biochemistry, Genetics and Molecular Biology
Ponatinib
100%
Tyrosine Kinase Inhibitor
66%
Cell Function
33%
Kinase Insert Domain Receptor
33%
Myeloid
16%
Angiogenesis
16%
Cell Viability
16%
Endothelial Progenitor Cell
16%
Antiangiogenic Activity
16%
Imatinib
16%
Programmed Cell Death
16%
Nilotinib
16%
Pharmacology, Toxicology and Pharmaceutical Science
Ponatinib
100%
Adverse Event
66%
Protein Tyrosine Kinase Inhibitor
66%
Vasculotropin Receptor 2
33%
Cell Viability
16%
Imatinib
16%
Chronic Myeloid Leukemia
16%
Antiangiogenic
16%
Nilotinib
16%